Physician profile
Patrick Tiedeken
NPI 1013994805
$478.35
in general payments reported to CMS, 2019-2025
9 companies · $98.57 in 2025
The $98.57 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.87 · 2020: $39.75 · 2021: $32.05 · 2022: $27.59 · 2023: $102 · 2024: $125 · 2025: $98.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $176.74 | 2023-2024 | Vyzulta |
| Biotissue Holdings INC. | $113.52 | 2019-2025 | |
| Abbvie INC. | $60.21 | 2022-2023 | Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $36.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.36 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Vision LLC | $17.16 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.16 | 2023 | Cequa |
| Allergan, INC. | $14.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tiedeken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.